Conquering Diseases Driven

By Excess Inflammation

BioAegis is pioneering life-saving treatments for severe inflammatory conditions by advancing a platform built around plasma gelsolin (pGSN), a naturally occurring immune regulator protein.

While current therapies suppress the immune system, leaving many patients vulnerable to infection and other serious side effects, plasma gelsolin works differently. Its multi-faceted mechanism restores balance to the immune system rather than shutting it down, setting a new standard for treating inflammatory diseases.

Advancing Breakthroughs with Strategic Partnerships and Global Potential

We’ve built a strong foundation for growth through innovation, strategic partnerships, and market insight. Our expanding patent portfolio secures our core technology, while collaborations with leading research institutions and industry partners accelerate development and validation. With clear visibility into high-value market opportunities and a disciplined approach to execution, we are well positioned to deliver breakthrough therapies that address critical unmet needs.

> 40

PATENTS

20+

COLLABORATORS

$50B

MARKET POTENTIAL

Plasma Gelsolin Deficiency: A Hidden Driver of Disease Severity

When the body faces infection, trauma, or inflammation, plasma gelsolin (pGSN) goes to work—neutralizing inflammatory molecules and restoring balance. But in many serious conditions, this vital protein becomes depleted faster than it can be replenished, leading to Plasma Gelsolin Deficiency (PGD).

Once pGSN levels drop, the immune system loses control, allowing inflammation to spread unchecked. Low pGSN is a powerful biomarker of worsening disease, linked to higher rates of organ failure, morbidity, and mortality across a wide range of inflammatory and infectious disorders. Addressing this deficiency represents a promising new frontier in restoring immune balance and improving outcomes.

“Plasma gelsolin is thought be an important anti-inflammatory protein… Low levels correlating with mortality could be an important biomarker for disease and may suggest a potential therapeutic role for exogenously administered gelsolin.”

“Inflammation has hit the big time. Over the past decade, it has become widely accepted that inflammation is a driving force behind chronic diseases that will kill nearly all of us. Cancer. Diabetes and obesity. Alzheimer’s disease. Atherosclerosis. Here, inflammation wears a grim mask, shedding its redeeming features and making sick people sicker…..”

“Antimicrobial resistance is an urgent global public health threat, killing at least 1.27 million people worldwide and associated with nearly 5 million deaths in 2019. In the U.S., more than 2.8 million antimicrobial-resistant infections occur each year.”

Creating a Paradigm Shift in Treating Inflammatory Diseases

Plasma gelsolin, a single human protein is redefining the way inflammatory diseases are treated. Rather than suppressing the immune system, it works by restoring balance—enabling the body to keep inflammation localized and controlled, preventing the damaging, system-wide response that drives severe disease.

REGULATES
INFLAMMATION

REGULATES INFLAMMATION

Plasma gelsolin's unique role is to modulate the necessary inflammatory response so that what was intended to be a mechanism of healing does not become an instrument of morbidity and death.

ACUTE AND CHRONIC DISEASE APPLICATIONS

Multiple disease applications --- $50 billion pipeline market opportunity.

KEY COMPONENT OF
INNATE IMMUNITY

KEY COMPONENT OF INNATE IMMUNITY

Plasma Gelsolin is a key component of the innate immune system - the first line of defense against threats to the body. This innate system is not pathogen-specific and reacts equally well to a wide variety of organisms.

NON IMMUNOSUPPRESSIVE

Most agents which interfere with the inflammatory process cause immunosuppression in patients. Plasma gelsolin is unique in that it is not immunosuppressive.

BENIGN SAFETY PROFILE

Recombinant human plasma gelsolin has been manufactured to be identical to the natural human protein. No serious side effects were identified in animal toxicology studies or four human studies when dosed either intravenously or by inhalation, even at the highest levels.

EXTENSIVE IP PORTFOLIO

Our original IP and know-how was licensed from a consortium of Harvard institutions and other collaborators resulting in more than 40 patents being granted globally to date. Plasma gelsolin will benefit from 12 years of biologics exclusivity in the US beginning at approval of the product and data exclusivity of 11 years in the EU.

error: Content is protected !!